Table of Contents Author Guidelines Submit a Manuscript
Volume 11 (2011), Pages 2124-2135
Research Article

Advantages and Disadvantages of Hyperbaric Oxygen Treatment in Mice with Obesity Hyperlipidemia and Steatohepatitis

1Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
2Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan
3Department of Japanese Oriental Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
4Institute for Animal Reproduction, 1103 Fukaya, Kasumigaura-shi, Ibaraki 300-0134, Japan
5Faculty of Pharmacy, Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishitokyo-shi, Tokyo 202-8585, Japan
6School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
7Department of Hyperbaric Medicine and Neurology, Cardinal Tien Hospital, New Taipei City, Taiwan

Received 30 August 2011; Accepted 15 October 2011

Academic Editors: M. Elisaf and E. Macken

Copyright © 2011 Koichi Tsuneyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The effect of hyperbaric oxygen treatment (HBOT) was examined using MSG mice, which are an animal model of obesity, hyperlipidemia, diabetes, and nonalcoholic fatty liver disease. Nineteen MSG male mice were divided into HBOT treated and control groups at 12 weeks of ages. The HBOT group was treated with hyperbaric oxygen from 12 to 14 weeks (first phase) and then from 16 to 18 weeks (second phase). Interestingly, the body weight of the HBOT group was significantly lower ( 𝑃 < 0 . 0 1 ) than that of the control group. In contrast, the serum lipid level did not show significant changes between the two groups. As for the effects of increasing oxidative stress, the liver histology of the HBOT group showed severer cellular damage and aberrant TNF-α expression. HBOT has the advantage of improving obesity in patients with metabolic syndrome, but the fault of causing organ damage by increasing oxidative stress.